| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2d2fdd3b50079b2a618b2785106c24d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_234d013a45d0e2712b9fbd93f9dccf1b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-44 |
| filingDate |
2022-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff79b1b5267bd30ebe9ea9ae5f6eded6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f872f04f239176181612f9e64e9ab771
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76f19d6c30441f2b8a85d285e9150deb |
| publicationDate |
2022-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022411418-A1 |
| titleOfInvention |
Cdgsh iron sulfur domain 2 activators and use thereof |
| abstract |
Isoindoline compounds and their pharmaceutical compositions. Also provided are methods of treating a Cisd2-insufficiency associated disorder and protecting against doxorubicin-induced cardiotoxicity. |
| priorityDate |
2021-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |